Skin Cancer (Non-Melanoma)

Non-melanoma skin cancers are the most common malignancies worldwide. Basal cell carcinoma is driven by Hedgehog pathway activation and treated with Hedgehog inhibitors (vismodegib, sonidegib) or cemiplimab when advanced; cutaneous squamous cell carcinoma responds to the PD-1 inhibitors cemiplimab and pembrolizumab; and Merkel cell carcinoma — a rare, aggressive neuroendocrine skin cancer — achieves durable responses with PD-1/PD-L1 checkpoint blockade (avelumab, pembrolizumab, nivolumab). Melanoma is covered on its own dedicated page.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Skin Cancer (Non-Melanoma)

• Cemiplimab (Libtayo) — Checkpoint Inhibitor
• Pembrolizumab (Keytruda) — Checkpoint Inhibitor
• Vismodegib (Erivedge) — Other
• Sonidegib (Odomzo) — Other
• Avelumab (Bavencio) — Checkpoint Inhibitor
• Nivolumab (Opdivo) — Checkpoint Inhibitor